RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer (NCT05966194)
A Randomized Placebo-Controlled Trial of Two Schedules of RRx-001 for the Attenuation of Severe Oral Mucositis in Patients Receiving Concomitant Chemoradiation for the Treatment of Locally Advanced Squamous Cell Carcinoma of the Oral Cavity or Oropharynx
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to determine if RRx-001, which is added on to the cisplatin and radiation treatment, reduces the incidence of severe oral mucositis in patients with head and neck cancers. All patients in this study will receive 7 weeks of standard of care radiation therapy given with the chemotherapy agent, cisplatin. Patients will receive RRx-001 or placebo before start of standard of care treatment.
Who can join: Review the eligibility criteria below.
Location: Banner MD Anderson Cancer Center — Gilbert, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (14 Sites)
- Banner MD Anderson Cancer Center — Gilbert, Arizona
- The University of Arizona Cancer Center — Tucson, Arizona
- Miami Cancer Institute — Miami, Florida
- Northwestern University Feinberg School of Medicine — Chicago, Illinois
- Parkview Cancer Institute — Fort Wayne, Indiana
- Willis Knighton Cancer Center — Shreveport, Louisiana
- Sandra and Malcolm Berman Cancer Institute — Baltimore, Maryland
- University of Michigan — Ann Arbor, Michigan
- Renown Regional Medical Center — Reno, Nevada
- East Carolina University School of Medicine — Greenville, North Carolina
- The Ohio State University James Cancer Hospital & Solove Research Institute — Columbus, Ohio
- Ballad Health — Johnson City, Tennessee
- University of Texas Southwestern Medical Center — Dallas, Texas
- University of Virginia — Charlottesville, Virginia
📞 Contact the Study Coordinator
Phone: (877) 632-6789
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Oral Mucositis
- Photobiomodulation for the Prevention of Oral Mucositis — Boston, Massachusetts
- Coconut Oil to Prevent Mouth Sores in Pediatric Patients Receiving High Dose Chemotherapy — Charlotte, North Carolina
- F.L.O.S.S. Project (Facilitated Lessons on Oral and Systemic Health in Survivors) — Washington D.C., District of Columbia
Explore by condition: All Oral Mucositis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.